FM-VP4 Forbes Medi-Tech.
FM-VP4 is a phytosterol analog under development by Forbes Medi-Tech for the potential treatment of hyperlipidemia and hypercholesterolemia. By March 2002, FM-VP4 had entered phase I clinical trials and phase II trials were underway by late 2002.
Department of Core Clinical Pathology & Biochemistry, Royal Perth Hospital, School of Surgery and Pathology, University of Western Australia, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au
John R
JR
Burnett
D000818:Animals; D008078:Cholesterol, LDL / Q000097:blood; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D015394:Molecular Structure; D010840:Phytosterols / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship
D008078:Cholesterol, LDL; C445524:FM-VP4 compound; D000960:Hypolipidemic Agents; D010840:Phytosterols